Plain-English translation of NCT06863311 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new drug called zanzalintinib to see if it can help people whose kidney cancer came back or worsened after they received an earlier immunotherapy treatment. You would be randomly assigned to either take zanzalintinib by itself, or take it combined with another immunotherapy medication called . The researchers want to find out which approach works better for controlling the cancer.
Many people with advanced kidney cancer initially respond to immunotherapy, but their cancer can start growing again. This trial is designed to find a new treatment option for those patients, hoping that this medication—either alone or paired with another immunotherapy—might help when the first treatment stops working.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take the medication in 4-week treatment cycles. You'll either take a daily pill by itself, or take a daily pill combined with an intravenous infusion of immunotherapy given once every 4 weeks. You'll continue treatment as long as the cancer is not growing and you are tolerating the medication well. Throughout the trial, you'll have regular blood tests and scans to check how the cancer is responding.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States